Recently, nintedanib, an inhibitor that targets multiple RTKs as well as Src kinases has been approved to treat patients with idiopathic pulmonary fibrosis [24], suggesting that Src could be a therapeutic target in fibrotic diseases. This evidence concerns the gene SRC and idiopathic pulmonary fibrosis.